Marcia Cruz-Correa, Chief Medical Officer at PanOncology Trials, shared a post on X:
“Participating in ASCO GI 2025 Gastric Cancer 1st line therapy biomarkers including HER2, PDL1 and CLDN18 are vital to guide targeted therapy.
Clinical trails are available and integrate these biomarkers.”
